Current Treatment Considerations for Osteosarcoma Metastatic at Presentation

医学 骨肉瘤 放射治疗 化疗 帕唑帕尼 异环磷酰胺 卡铂 养生 肿瘤科 外科 内科学 顺铂 癌症 病理 舒尼替尼
作者
Shinji Tsukamoto,Costantino Errani,Andrea Angelini,Andreas F. Mavrogenis
出处
期刊:Orthopedics [SLACK, Inc.]
卷期号:43 (5) 被引量:47
标识
DOI:10.3928/01477447-20200721-05
摘要

Approximately one-fourth of osteosarcoma patients have metastases at presentation. The best treatment options for these patients include chemotherapy, surgery, and radiotherapy; however, the optimal scheme has not yet been defined. Standard chemotherapy for osteosarcoma metastatic at presentation is based on high-dose methotrexate, doxorubicin, and cisplatin (the MAP regimen), with the possible addition of ifosfamide. Surgical treatment continues to be fundamental; complete surgical resection of all sites of disease (primary and metastatic) remains essential for survival. In patients whose tumors do not respond to neoadjuvant chemotherapy, early surgical resection of the primary tumor with limb-salvage surgery or amputation and multiple metastasectomies, if feasible, after the completion of adjuvant chemotherapy is a reasonable option, as the reduction of the tumor volume could probably increase the effect of chemotherapy. Advanced radiotherapy techniques, such as carbon ion radiotherapy and stereotactic radiosurgery, and molecular targeted chemo-therapy with drugs such as pazopanib or apatinib have improved the dismal prognosis, especially for patients who are medically inoperable or who refuse surgery. Given that the presence of metastatic disease at diagnosis of a patient with osteosarcoma is a poor prognostic factor, a multidisciplinary approach by surgeons, medical oncologists, and radiotherapists is important. [ Orthopedics . 2020;43(5):e345–e358.]

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
shisui发布了新的文献求助30
刚刚
1秒前
吉祥应助忧郁丝采纳,获得10
1秒前
善学以致用应助初余采纳,获得10
3秒前
ding应助Laraine采纳,获得10
3秒前
3秒前
3秒前
li完成签到 ,获得积分10
4秒前
怡然的友安完成签到,获得积分10
5秒前
稳重的烙发布了新的文献求助10
6秒前
汉堡包应助杨志坚采纳,获得10
6秒前
gjy完成签到,获得积分10
6秒前
Hyde驳回了今后应助
6秒前
7秒前
7秒前
哭泣的丝完成签到 ,获得积分10
7秒前
脑洞疼应助杨威采纳,获得10
7秒前
刘奶奶的牛奶完成签到,获得积分10
9秒前
10秒前
shisui完成签到,获得积分10
10秒前
10秒前
诚心冬亦完成签到,获得积分10
11秒前
桐桐应助leo采纳,获得30
11秒前
11秒前
12秒前
QLLW完成签到,获得积分10
12秒前
chen发布了新的文献求助50
12秒前
hjx完成签到,获得积分10
13秒前
橘色天际线完成签到,获得积分10
13秒前
Hello应助55采纳,获得10
13秒前
14秒前
14秒前
momo完成签到,获得积分10
15秒前
Banbor2021发布了新的文献求助50
15秒前
15秒前
16秒前
史鸿完成签到,获得积分10
16秒前
黄紫红蓝发布了新的文献求助10
16秒前
高分求助中
The ACS Guide to Scholarly Communication 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3069389
求助须知:如何正确求助?哪些是违规求助? 2723274
关于积分的说明 7481149
捐赠科研通 2370322
什么是DOI,文献DOI怎么找? 1256943
科研通“疑难数据库(出版商)”最低求助积分说明 609763
版权声明 596852